Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
NCT04224337
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
16
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG:
Durvalumab + doxorubicin + ifosfamide
Sponsor
Seoul National University Hospital